| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Mrsa Update: Cepheid, Basilea And Nektar
Posted on 10/30/2007 19:16 PM | Link | Post Comment
by Michael Shulman
BiotechBlitz
The news and activity surrounding the killer-staph infection, MRSA, is increasing. A brief update and then a couple of companies of interest:
• Senator Richard Durbin of Illinois is set to introduce MRSA legislation next week. This bill would require a government agency -- the Agency for Healthcare Research and Quality -- to promulgate guidelines on how to control MRSA and other hospital-acquired infections. The bill would force hospitals to report infection rates to the CDC. This action follows, by one day, a call by Senator Charles (Chuck) Schumer of New York for hospital reporting of infections.
• A recent study showed MRSA has spread to the animal population, possibly from pets serving as companions to people in nursing homes and other long-term café facilities.
• More and more cases of non-hospital-acquired MRSA are being reported around the country, mostly in schools and mostly among athletes or kids frequenting athletic facilities.
• So far, the tort lawyers are not involved. Stay tuned.
Why do I mention tort lawyers? Because several countries in Europe have virtually eliminated MRSA and the U.S. Dept. of Veterans Affairs reduced it 75% in a pilot program.
The infection can be contained and perhaps eradicated over time in a hospital setting, BUT a hospital with a bad infection rate is going to be a target for these attorneys. Go get ‘em, I say!
That will get the hospitals' collective butts in gear. There is no excuse for the level of infections and the thousands of deaths – the CDC suggests at least 17,000 per annum – caused by MRSA.
Is there money to be made? Check it out yourself – the best and increasingly dominant test is from Cepheid (CPHD). I own the stock. And a new form of antibiotic is being developed by Basilea (SWX: BSLN). Nektar (NKTR) is working on an inhaled form of antibiotic useful in niches.
BiotechBlitz is a regular contributor to BioHealth Investor
___________________
BiotechBlitz
The news and activity surrounding the killer-staph infection, MRSA, is increasing. A brief update and then a couple of companies of interest:
• Senator Richard Durbin of Illinois is set to introduce MRSA legislation next week. This bill would require a government agency -- the Agency for Healthcare Research and Quality -- to promulgate guidelines on how to control MRSA and other hospital-acquired infections. The bill would force hospitals to report infection rates to the CDC. This action follows, by one day, a call by Senator Charles (Chuck) Schumer of New York for hospital reporting of infections.
• A recent study showed MRSA has spread to the animal population, possibly from pets serving as companions to people in nursing homes and other long-term café facilities.
• More and more cases of non-hospital-acquired MRSA are being reported around the country, mostly in schools and mostly among athletes or kids frequenting athletic facilities.
• So far, the tort lawyers are not involved. Stay tuned.
Why do I mention tort lawyers? Because several countries in Europe have virtually eliminated MRSA and the U.S. Dept. of Veterans Affairs reduced it 75% in a pilot program.
The infection can be contained and perhaps eradicated over time in a hospital setting, BUT a hospital with a bad infection rate is going to be a target for these attorneys. Go get ‘em, I say!
That will get the hospitals' collective butts in gear. There is no excuse for the level of infections and the thousands of deaths – the CDC suggests at least 17,000 per annum – caused by MRSA.
Is there money to be made? Check it out yourself – the best and increasingly dominant test is from Cepheid (CPHD). I own the stock. And a new form of antibiotic is being developed by Basilea (SWX: BSLN). Nektar (NKTR) is working on an inhaled form of antibiotic useful in niches.
BiotechBlitz is a regular contributor to BioHealth Investor
___________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Credit Bloggers
- Don't Mess With Taxes
- Invest2Success
- Land of Black Gold
- Piggington's Econo-Almanac
- Financial Rounds
Examples
Underground Trading - Sat May 10, 2008 04:02PM
This is an update on my speculative long term position p [read more]
This is an update on my speculative long term position p [read more]
Morpheus Trading - Mon May 12, 2008 04:25AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Millionaire Now! by Larry Nusbaum - Mon May 12, 2008 04:54AM
MORNING MARKET COMMENTARYfor Monday, May 12, 2008Weak Financ [read more]
MORNING MARKET COMMENTARYfor Monday, May 12, 2008Weak Financ [read more]
<< My Home | TheMoneyBlogs Home